Kosiborod, Mikhail N.

Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic control

Inzucchi, S. E., Kosiborod, M., Fitchett, D., Wanner, C., Hehnke, U., Kaspers, S., George, J. T., & Zinman, B. (2018) · Circulation

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 162

Introduction and Methodology: Standards of Care in Diabetes—2025

American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Callaghan, B. C., et al. (2025) · Diabetes Care

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 155

Type 2 diabetes mellitus and heart failure, a scientific statement from the American Heart Association and Heart Failure Society of America

Dunlay, S. M., Givertz, M. M., Aguilar, D., Allen, L. A., Chan, M., Desai, A. S., Deswal, A., Dickson, V. V., Kosiborod, M. N., Lekavich, C. L., et al. (2019) · Journal of Cardiac Failure

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 145

Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR® Research to Practice project

Arnold, S. V., Inzucchi, S. E., Tang, F., McGuire, D. K., Mehta, S. N., Maddox, T. M., Goyal, A., Sperling, L. S., Einhorn, D., Wong, N. D., et al. (2017) · European Journal of Preventive Cardiology

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 144

Biomarker-based risk prediction of incident heart failure in pre-diabetes and diabetes

Pandey, A., Vaduganathan, M., Patel, K. V., Ayers, C., Ballantyne, C. M., Kosiborod, M. N., Carnethon, M., DeFilippi, C., McGuire, D. K., Khan, S. S., et al. (2021) · JACC: Heart Failure

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 144

Anemia and Outcomes in Patients With Heart Failure: A Study From the National Heart Care Project

Kosiborod, M., Curtis, J. P., Wang, Y., Smith, G. L., Masoudi, F. A., Foody, J. M., Havranek, E. P., & Krumholz, H. M. (2005) · Archives of Internal Medicine

Erythropoietin and Anemia TreatmentHeart Failure Treatment and Management

Cited by 142

Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization

Khan, M. S., Fonarow, G. C., McGuire, D. K., Hernandez, A. F., Vaduganathan, M., Rosenstock, J., Handelsman, Y., Verma, S., Anker, S. D., McMurray, J. J. V., et al. (2020) · Circulation

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 139

Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)

Serenelli, M., Böhm, M., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Solomon, S. D., DeMets, D. L., et al. (2020) · European Heart Journal

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 138

Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial

Pratley, R. E., Tuttle, K. R., Rossing, P., Rasmussen, S., Perkovic, V., Nielsen, O. W., Mann, J. F. E., MacIsaac, R. J., Kosiborod, M. N., Kamenov, Z., et al. (2024) · Journal of the American College of Cardiology

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 132

Use of Guideline-Recommended Risk Reduction Strategies Among Patients With Diabetes and Atherosclerotic Cardiovascular Disease: Insights From Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD)

Arnold, S. V., de Lemos, J. A., Rosenson, R. S., Ballantyne, C. M., Liu, Y., Mues, K. E., Alam, S., Elliott-Davey, M., Bhatt, D. L., Cannon, C. P., et al. (2019) · Circulation

Diabetes, Cardiovascular Risks, and LipoproteinsClinical practice guidelines implementation

Cited by 130

Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses

Kosiborod, M. N., Bhatta, M., Davies, M., Deanfield, J. E., Garvey, W. T., Khalid, U., Kushner, R., Rubino, D. M., Zeuthen, N., & Verma, S. (2023) · Diabetes, Obesity and Metabolism

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 127

Glycemic Control, Cardiac Autoimmunity, and Long-Term Risk of Cardiovascular Disease in Type 1 Diabetes Mellitus: A DCCT/EDIC Cohort–Based Study

Sousa, G. R., Pober, D., Galderisi, A., Lv, H., Yu, L., Pereira, A. C., Doria, A., Kosiborod, M., & Lipes, M. A. (2019) · Circulation

Diabetes and associated disordersDiabetes Management and Research

Cited by 117

Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials

Verma, S., Bhatta, M., Davies, M., Deanfield, J. E., Garvey, W. T., Jensen, C., Kandler, K., Kushner, R. F., Rubino, D. M., & Kosiborod, M. N. (2023) · eClinicalMedicine

Adipokines, Inflammation, and Metabolic DiseasesPharmacology and Obesity Treatment

Cited by 106

Effects of semaglutide on symptoms, function, and quality of life in patients with heart failure with preserved ejection fraction and obesity: a prespecified analysis of the STEP-HFpEF trial

Kosiborod, M. N., Verma, S., Borlaug, B. A., Butler, J., Davies, M. J., Jon Jensen, T., Rasmussen, S., Erlang Marstrand, P., Petrie, M. C., Shah, S. J., et al. (2024) · Circulation

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 104

Legacy benefits of blood glucose, blood pressure and lipid control in individuals with diabetes and cardiovascular disease: Time to overcome multifactorial therapeutic inertia?

Khunti, K., Kosiborod, M., & Ray, K. K. (2018) · Diabetes, Obesity and Metabolism

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management

Cited by 104

Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype

Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Christensen, L., Davies, M., Hovingh, K. G., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · JACC: Heart Failure

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 97

Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF

Docherty, K. F., Jhund, P. S., Anand, I., Bengtsson, O., Böhm, M., de Boer, R. A., DeMets, D. L., Desai, A. S., Drozdz, J., Howlett, J., et al. (2020) · Circulation

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 95

Semaglutide and NT-proBNP in Obesity-Related HFpEF

Petrie, M. C., Borlaug, B. A., Butler, J., Davies, M. J., Kitzman, D. W., Shah, S. J., Verma, S., Jensen, T. J., Einfeldt, M. N., Liisberg, K., et al. (2024) · Journal of the American College of Cardiology

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 95

Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER

Arnold, S. V., Tang, F., Cooper, A., Chen, H., Gomes, M. B., Rathmann, W., Shimomura, I., Vora, J., Watada, H., Khunti, K., et al. (2022) · BMC Endocrine Disorders

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 86

Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Reduced Ejection Fraction

Kosiborod, M. N., Bhatt, A. S., Claggett, B. L., Vaduganathan, M., Kulac, I. J., Lam, C. S. P., Hernandez, A. F., Martinez, F. A., Inzucchi, S. E., Shah, S. J., et al. (2023) · Journal of the American College of Cardiology

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 86

Use of intensive glycemic management in older adults with diabetes mellitus

Arnold, S. V., Lipska, K. J., Wang, J., Seman, L., Mehta, S. N., & Kosiborod, M. (2018) · Journal of the American Geriatrics Society

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 74

Risk of atrial fibrillation in people with type 1 diabetes compared with matched controls from the general population: a prospective case-control study

Dahlqvist, S., Rosengren, A., Gudbjörnsdottir, S., Pivodic, A., Wedel, H., Kosiborod, M., Svensson, A.-M., & Lind, M. (2017) · The Lancet Diabetes & Endocrinology

Atrial Fibrillation Management and OutcomesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 70

DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases

Handelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Beckman, J. A., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., et al. (2022) · Journal of Diabetes and its Complications

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 64

GLP-1 Receptor Agonists and Sight-Threatening Ophthalmic Complications in Patients With Type 2 Diabetes

Ramsey, D. J., Makwana, B., Dani, S. S., Patel, M., Panchal, K., Shah, J., Khadke, S., Kumar, A., Patel, T., Kosiborod, M. N., et al. (2025) · JAMA Network Open

Diabetes Treatment and ManagementRetinal Diseases and Treatments

Cited by 63